2 results match your criteria: "San Francisco GeneralHospital[Affiliation]"
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.
Clin Infect Dis
January 2009
Division of Pulmonary and Critical Care Medicine, University of California-San Francisco, San Francisco GeneralHospital, 1001 Potrero Ave., San Francisco, CA 94110, USA.
Background: Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described.
Methods: Medical charts were retrospectively reviewed for all cases of culture-confirmed, INH-monoresistant tuberculosis ( n = 137) reported to the San Francisco Department of Public Health Tuberculosis Control Section from October 1992 through October 2005, and those cases were compared with a time-matched sample of drug-susceptible tuberculosis cases (n = 274)
Results: In multivariate analysis, only a history of treatment for latent tuberculosis (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.
Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.
Curr Ther Res Clin Exp
September 2005
Department of Medical Science, Roche Laboratories, Inc, Nutley, New Jersey, USA.
Background: Hepatitis C virus (HCV) infection is the most common blood-borne virus in the United States. Several mono- and combination therapies have been approved by the US Food and Drug Administration for the treatment of HCV, but their routes of administration, dosing approaches, eras of introduction, and actual use in clinical practice and resulting effectiveness have not yet been reported.
Objectives: The aim of this article was to characterize clinical use and virologic response (VR) of the HCV treatments interferon alfa-2b plus ribavirin (IFN + RBV) and peginterferon alfa-2b plus ribavirin (peg-IFN + RBV).